Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report)’s share price traded up 9.1% during mid-day trading on Friday . The stock traded as high as GBX 1.22 ($0.02) and last traded at GBX 1.22 ($0.02). 5,081,744 shares changed hands during mid-day trading, a decline of 43% from the average session volume of 8,916,152 shares. The stock had previously closed at GBX 1.11 ($0.01).
Hemogenyx Pharmaceuticals Trading Up 24.7 %
The firm’s 50 day moving average price is GBX 1.38 and its 200-day moving average price is GBX 1.43. The company has a debt-to-equity ratio of 92.09, a current ratio of 4.38 and a quick ratio of 6.72. The stock has a market cap of £18.61 million, a P/E ratio of -111.40 and a beta of 3.14.
About Hemogenyx Pharmaceuticals
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Further Reading
- Five stocks we like better than Hemogenyx Pharmaceuticals
- EV Stocks and How to Profit from Them
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- What is Forex and How Does it Work?
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- Learn Technical Analysis Skills to Master the Stock Market
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
